GGrantIndex
← Leaderboards

Benjamin J. Morasco

Oregon Health & Science University

$9,178,588
Attributed
$12,142,738
Total exposure
7
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.5M · FY200825
$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,918,881 · 5
FDA$223,857 · 1
VA$0 · 1

By mechanism

UH3$5,197,675 · 1
R01$5,161,524 · 2
K23$829,057 · 1
UG3$730,625 · 1
U01$223,857 · 1
I01$0 · 1

Top collaborators

Most similar at Oregon Health & Science University

Same institution · by research overlap

Others in their field

Top investigators on “Chronic Pain

Research focus

Chronic PainParticipantQuality Of LifeChronicBasePain IntensityOpioidPainPain ManagementAlcohol Or Other Drugs UsePharmaceutical PreparationsPrescription OpioidChronic Pain PatientClinical CareAdverse EffectsReportingAddictionSafetyBiopsychosocialSamplingImpairmentPatient Self-ReportDrug TestingModification

Grant awards (27)

Tele-Collaborative Outreach to Rural Patients with Chronic Pain: The CORPs Trial$2,525,095
UH3 · FY2025 · AT
Tele-Collaborative Outreach to Rural Patients with Chronic Pain: The CORPs Trial$1,304,577
UH3 · FY2024 · AT
Tele-Collaborative Outreach to Rural Patients with Chronic Pain: The CORPs Trial$1,368,003
UH3 · FY2023 · AT
Impact of Prescription Opioid Dose Changes on Cannabis Use and Clinical Outcomes$541,509
R01 · FY2023 · DA · contact PI
Tele-Collaborative Outreach to Rural Patients with Chronic Pain: The CORPs Trial$730,625
UG3 · FY2022 · AT
Impact of Prescription Opioid Dose Changes on Cannabis Use and Clinical Outcomes$561,365
R01 · FY2022 · DA · contact PI
Impact of Prescription Opioid Dose Changes on Cannabis Use and Clinical Outcomes$564,053
R01 · FY2021 · DA · contact PI
Impact of Prescription Opioid Dose Changes on Cannabis Use and Clinical Outcomes$547,764
R01 · FY2020 · DA · contact PI
A Patient-Centered Intervention to Improve Opioid Safety$0
I01 · FY2020 · VA · contact PI
A Patient-Centered Intervention to Improve Opioid Safety$0
I01 · FY2020 · VA · contact PI
A Patient-Centered Intervention to Improve Opioid Safety$0
I01 · FY2020 · VA · contact PI
A Patient-Centered Intervention to Improve Opioid Safety$0
I01 · FY2020 · VA · contact PI
Impact of Prescription Opioid Dose Changes on Cannabis Use and Clinical Outcomes$537,390
R01 · FY2019 · DA · contact PI
A Patient-Centered Intervention to Improve Opioid Safety$0
I01 · FY2019 · VA · contact PI
Correlates and outcomes of opioid dose escalation among chronic pain patients$435,336
R01 · FY2017 · DA · contact PI
Correlates and outcomes of opioid dose escalation among chronic pain patients$428,266
R01 · FY2016 · DA · contact PI
Correlates and outcomes of opioid dose escalation among chronic pain patients$494,186
R01 · FY2015 · DA · contact PI
Correlates and outcomes of opioid dose escalation among chronic pain patients$509,574
R01 · FY2014 · DA · contact PI
Reducing Prescription Opioid Misuse and Abuse with Urine Drug Testing$74,619
U01 · FY2014 · FD · contact PI
Correlates and outcomes of opioid dose escalation among chronic pain patients$542,081
R01 · FY2013 · DA · contact PI
Reducing Prescription Opioid Misuse and Abuse with Urine Drug Testing$74,619
U01 · FY2013 · FD · contact PI
Chronic Pain and Substance Use in Patients with Hepatitis C$166,684
K23 · FY2012 · DA · contact PI
Reducing Prescription Opioid Misuse and Abuse with Urine Drug Testing$74,619
U01 · FY2012 · FD · contact PI
Chronic Pain and Substance Use in Patients with Hepatitis C$166,684
K23 · FY2011 · DA · contact PI
Chronic Pain and Substance Use in Patients with Hepatitis C$162,551
K23 · FY2010 · DA · contact PI
Chronic Pain and Substance Use in Patients with Hepatitis C$167,605
K23 · FY2009 · DA · contact PI
Chronic Pain and Substance Use in Patients with Hepatitis C$165,533
K23 · FY2008 · DA · contact PI